RecruitingNot Applicable

Impact of Thyroid Hormones on Human Glucose and Energy Metabolism

Germany60 participantsStarted 2026-02-04

Plain-language summary

The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with initial diagnosis of graves disease OR * patients with initial diagnosis of thyroid carcinoma Exclusion Criteria: * contraindications for oral glucose tolerance test * Diabetes mellitus * Fasting glucose level ≥ 200 mg/dL * Exogenous insulin administration with action at the time of the test * Current disease with activation of stress hormones * Post-aggressive metabolism * Acute infectious disease

What they're measuring

Insulin sensitivity

Timeframe: Baseline, 2 weeks, 3 months

Insulin secretion

Timeframe: Baseline, 2 weeks, 3 months

Trial details

NCT IDNCT07410637

SponsorUniversity of Ulm

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-02

Contact for this trial

Martin Heni, Prof

+4973150044505 martin.heni@uniklinik-ulm.de

View on ClinicalTrials.gov More Graves Disease trials